Submissions from 2021
Modified RANO (mRANO), iRANO, and standard RANO response to convection-enhanced delivery of IL4R-targeted immunotoxin MDNA55 in recurrent glioblastoma, Sajeel Chowdhary and Frank Vrionis
Full Text Restricted – Available from BHSF IP or login only
Regression of Intracranial Meningiomas Following Treatment with Cabozantinib, Rupesh Kotecha, Raees Tonse, Haley Appel, Yazmin Odia, Guilherme Rabinowits, and Minesh Mehta
Open Access
Systematic review and meta-analysis of breast cancer brain metastasis and primary tumor receptor expression discordance, Rupesh Kotecha, Raees Tonse, Muni Rubens, Michael McDermott, Yazmin Odia, Haley Appel, and Minesh Mehta
Open Access
Single agent activity of ONC201 in non-midline H3 K27M-mutant diffuse gliomas, Yazmin Odia, Matthew Hall, Doured Daghistani, and Minesh Mehta
A Phase 1/2 Study of Selinexor in Combination with Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma, Yazmin Odia and Minesh Mehta
Lumican, Pro-tumorigenic or Anti-tumorigenic: A Conundrum, Muni Rubens, Anshul Saxena, Peter McGranaghan, Yazmin Odia, and Rupesh Kotecha
Full Text Restricted – Available from BHSF IP or login only
Hospitalization rates for complications due to systemic therapy in the United States, Anshul Saxena, Muni Rubens, Venkataraghavan Ramamoorthy, Raees Tonse, Emir Veledar, Peter McGranaghan, Michael Chuong, Matthew Hall, Yazmin Odia, Minesh Mehta, and Rupesh Kotecha
Open Access
Chemotherapy-induced changes in tumor consistency can allow gross total resection of previously unresectable brainstem pilocytic astrocytoma, Vitaly Siomin and Yazmin Odia
Open Access
Submissions from 2020
CTIM-15. PRELIMINARY RESULTS OF A PHASE II STUDY OF NIVOLUMAB WITH HYPOFRACTIONATED RE-RADIATION AND BEVACIZUMAB FOR RECURRENT MGMT METHYLATED GLIOBLASTOMA, Minesh Mehta, Rupesh Kotecha, and Yazmin Odia
CTNI-17. CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA, Minesh Mehta, Yazmin Odia, Matthew Hall, and Doured Daghistani
HGG-18. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA, Minesh Mehta, Yazmin Odia, Matthew Hall, and Doured Daghistani
Open Access
DIPG-52. PHASE I CLINICAL TRIAL OF ONC201 IN PEDIATRIC H3 K27M-MUTANT GLIOMA OR NEWLY DIAGNOSED DIPG, Yazmin Odia, Matthew Hall, and Doured Daghistani
Open Access
ONC201 in previously irradiated pediatric H3 K27M-mutant glioma or newly diagnosed DIPG, Yazmin Odia, Matthew Hall, and Doured Daghistani
Biological activity of weekly ONC201 in adult recurrent glioblastoma patients, Yazmin Odia and Minesh Mehta
Full Text Restricted – Available from BHSF IP or login only
Clinical experience of ONC201 in patients with recurrent H3 K27M-mutant spinal cord glioma, Yazmin Odia and Minesh Mehta
Early imaging marker of progressing glioblastoma: a window of opportunity, Yazmin Odia and Minesh Mehta
Full Text Restricted – Available from BHSF IP or login only
Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma, Yazmin Odia and Minesh Mehta
RADT-31. PATTERNS OF CARE IN THE USE OF ADJUVANT RADIOTHERAPY AND CHEMOTHERAPY IN LOW GRADE GLIOMA PATIENTS IN THE UNITED STATES FROM 2010-2016, Warren Rehrer, Yazmin Odia, Muni Rubens, Noah Kalman, Michael Chuong, Rupesh Kotecha, Minesh Mehta, and Matthew Hall
The Use of Adjuvant Radiotherapy and Chemotherapy in Low Grade Glioma Patients in the United States from 2010-2016, Warren Rehrer, Muni Rubens, Katherine Von Werne, Yazmin Odia, Michael Chuong, Rupesh Kotecha, Minesh Mehta, and Matthew Hall
Full Text Restricted – Available from BHSF IP or login only
Recent Health Care Expenditure Trends Among Adult Cancer Survivors in United States, 2009-2016, Muni Rubens, Anshul Saxena, Sankalp Das, Chintan Bhatt, Emir Veledar, Peter McGranaghan, Ana Viamonte Ros, Yuliya Linhares, Yazmin Odia, Michael Chuong, Rupesh Kotecha, and Minesh Mehta
Full Text Restricted – Available from BHSF IP or login only
Submissions from 2019
EBV-positive primary CNS lymphoma restricted to the conus medullaris in an immunocompetent host, Matthew Hall, Lyle Feinstein, Sergio Gonzalez-Arias, and Yazmin Odia
Full Text Restricted – Available from BHSF IP or login only
First clinical experience with DRD2/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report, Matthew Hall, Yazmin Odia, Doured Daghistani, and Minesh Mehta
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201, Matthew Hall, Yazmin Odia, and Minesh Mehta
Full Text Restricted – Available from BHSF IP or login only
Core curriculum guidelines for a required clinical neurology experience, Yazmin Odia
Open Access
Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations, Yazmin Odia
Full Text Restricted – Available from BHSF IP or login only
Submissions from 2017
Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options, Yazmin Odia
Full Text Restricted – Available from BHSF IP or login only
BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors, Ashley Roque and Yazmin Odia
Full Text Restricted – Available from BHSF IP or login only
Submissions from 2016
Gangliocytomas and Gangliogliomas: Review of Clinical, Pathologic and Genetic Features, Yazmin Odia
Open Access
Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy, Yazmin Odia
Full Text Restricted – Available from BHSF IP or login only